BioSpace38m
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
FierceBiotech3h
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
DPA International on MSN1h
Annual core operating profit increases for British pharma GSK
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
GSK targets £40bn in sales as HIV and cancer drugs offset vaccine weakness
The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...
A small team of Australian scientists won a rare drug approval – and upended the pharma system
Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...
Budget 2025: Pfizer, Novartis, AstraZeneca to benefit from BCD exemptions; pharma stocks mixed
Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...
GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...